Search

Author/Creator Wasserman, Scott M.

1. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. (October 2013)

Authors:
Zannad, Faiez; Garcia, Angeles Alonso; Anker, Stefan D.; Armstrong, Paul W.; Calvo, Gonzalo; Cleland, John G.F.; Cohn, Jay N.; Dickstein, Kenneth; Domanski, Michael J.; Ekman, Inger; Filippatos, Gerasimos S.; Gheorghiade, Mihai; Hernandez, Adrian F.; Jaarsma, Tiny; Koglin, Joerg; Konstam, Marvin;...
Journal:
European journal of heart failure
Issue:
Volume 15:Number 10(2013)
Page Start:
1082
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Issue 7 (July 2018)

Authors:
Chan, Dick C.; Watts, Gerald F.; Somaratne, Ransi; Wasserman, Scott M.; Scott, Rob; Barrett, P. Hugh R.
Journal:
Arteriosclerosis, thrombosis, and vascular biology
Issue:
Volume 38:Issue 7(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. (September 2018)

Authors:
Wasserman, Scott M.; Sabatine, Marc S.; Koren, Michael J.; Giugliano, Robert P.; Legg, Jason C.; Emery, Maurice G.; Doshi, Sameer; Liu, Thomas; Somaratne, Ransi; Gibbs, John P.
Journal:
Journal of cardiovascular pharmacology and therapeutics
Issue:
Volume 23:Number 5(2018:Sep.)
Page Start:
423
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial. Issue 3 (4th March 2016)

Authors:
Nissen, Steven E.; Dent‐Acosta, Ricardo E.; Rosenson, Robert S.; Stroes, Erik; Sattar, Naveed; Preiss, David; Mancini, G.B. John; Ballantyne, Christie M.; Catapano, Alberico; Gouni‐Berthold, Ioanna; Stein, Evan A.; Xue, Allen; Wasserman, Scott M.; Scott, Rob; Thompson, Paul D.
Journal:
Clinical cardiology
Issue:
Volume 39:Issue 3(2016)
Page Start:
137
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Issue 10 (21st October 2018)

Authors:
Stroes, Erik; Robinson, Jennifer G.; Raal, Frederick J.; Dufour, Robert; Sullivan, David; Kassahun, Helina; Ma, Yuhui; Wasserman, Scott M.; Koren, Michael J.
Journal:
Clinical cardiology
Issue:
Volume 41:Issue 10(2018)
Page Start:
1328
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Design and rationale of the EBBINGHAUS trial: A phase 3, double‐blind, placebo‐controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid‐lowering therapy—A cognitive study of patients enrolled in the FOURIER trial. Issue 2 (16th February 2017)

Authors:
Giugliano, Robert P.; Mach, Francois; Zavitz, Kenton; Kurtz, Christopher; Schneider, Jingjing; Wang, Huei; Keech, Anthony; Pedersen, Terje R.; Sabatine, Marc S.; Sever, Peter S.; Honarpour, Narimon; Wasserman, Scott M.; Ott, Brian R.
Journal:
Clinical cardiology
Issue:
Volume 40:Issue 2(2017)
Page Start:
59
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment. (26th October 2016)

Authors:
Gibbs, John P.; Slatter, J. Greg; Egbuna, Ogo; Geller, Michelle; Hamilton, Lisa; Dias, Clapton S.; Xu, Ren Y.; Johnson, Jessica; Wasserman, Scott M.; Emery, Maurice G.
Journal:
Journal of clinical pharmacology
Issue:
Volume 57:Number 4(2017)
Page Start:
513
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Issue 1 (14th October 2016)

Authors:
Blom, Dirk J.; Koren, Michael J.; Roth, Eli; Monsalvo, Maria Laura; Djedjos, C. Stephen; Nelson, Patric; Elliott, Mary; Wasserman, Scott M.; Ballantyne, Christie M.; Holman, Rury R.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 19:Issue 1(2017)
Page Start:
98
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). (15th November 2016)

Authors:
Gibbs, John P.; Doshi, Sameer; Kuchimanchi, Mita; Grover, Anita; Emery, Maurice G.; Dodds, Michael G.; Gibbs, Megan A.; Somaratne, Ransi; Wasserman, Scott M.; Blom, Dirk
Journal:
Journal of clinical pharmacology
Issue:
Volume 57:Number 5(2017)
Page Start:
616
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗